Crescent Capital Partners
Australia's Crescent closes Fund VII on $670m
Crescent Capital Partners has closed its seventh Australia and New Zealand mid-market fund with AUD 1bn (USD 670m) in commitments.
Deal focus: IFM secures debut long-term capital deal
Targeting PRP Diagnostic Imaging through its long-hold fund meant IFM Investors could offer the company stability and partnership. It expects to generate dividend yield and capital growth
Blackstone buys Australia clinical trials specialist
The Blackstone Group has acquired Nucleus Network, which claims to be Australia’s largest phase-one clinical trials provider, for an undisclosed sum. It provides an exit for local GP Crescent Capital Partners.
Vintage update: Australia 2010-2012
A selection of Australia-based assets that remain in the portfolios of Advent Partners, Anchorage Capital Partners, CHAMP Ventures, and Crescent Capital Partners
Australia's PE-owned Tigerlily enters administration
Tigerlily, an Australian swimwear brand acquired by Crescent Capital Partners in 2017, has entered administration following a collapse in sales attributed to the COVID-19 outbreak.
Australia cross-border: Fool me once
Asian markets continue to represent an attractive destination for Australian PE-backed companies, but investors will need to show increasingly skeptical buyers that their cross-border plans have borne fruit
Crescent agrees $112m carve-out of Australia's Viridian Glass
Crescent Capital Partners has agreed to acquire Viridian Glass, a maker of float glass based in Australia and New Zealand, from building products manufacturer CSR for A$155 million ($112 million).
Crescent raises $586m for sixth Australia, New Zealand fund
Crescent Capital Partners has closed its sixth Australia and New Zealand mid-market fund at A$800 million ($586 million) after less than three months in the market.
Australia consumer: Attitude adjustment
Demographic shifts are prompting Australian GPs to reevaluate domestic consumer plays with an eye toward processes rather than goods. Overseas markets are an increasingly important part of the equation
Crescent buys Australian CRO business
Crescent Capital Partners has acquired Australia-based clinical research organization (CRO) Nucleus Network from The Baker Institute, an independent research institute that focuses on heart disease and diabetes.
Australia's Crescent loses partner
Tim Martin, a partner at Australian middle market private equity firm Crescent Capital Partners, has departed the firm ahead of its next fundraise.
Crescent sells Australia's GroundProbe to Orica
Australia's Crescent Capital Partners has sold domestic mining services technology supplier GroundProbe to explosives and blasting equipment company Orica for A$205 million ($157 million).
Crescent sells stake in Australia's ClearView Wealth for $111m
Crescent Capital Partners has agreed to sell a 14.9% stake in Australian financial services provider ClearView Wealth to Sony Life Insurance for approximately A$145 million ($111 million).
PE roll-ups: Consolidation game
Quadrant Private Equity's foray into the fitness club space represents the latest in a string of roll-up investments pursued by middle market Australian GPs. This strategy is a proven winner but execution risk should not be underestimated
Australia's Crescent exits Breezway to US trade buyer
Crescent Capital Partners sold Breezway, an Australian manufacturer of louvre windows for residential and commercial buildings, to US-based industry counterpart Jeld-Wen Holding.
Australia services: Roll-up rapport
As Australia rebalances its economy in the wake of the commodities downturn, services are coming to the fore. Private equity investors continue to see consolidation opportunities
Australia's Cardno backs improved buyout offer from Crescent
Crescent Capital Partners has moved closer to a buyout of Australian engineering company Cardno by winning board support for the deal with an improved offer.
Cardno board rejects takeover bid from Australia's Crescent
The board of Australian engineering company Cardno has advised shareholders to reject a buyout offer from Crescent Capital Partners on the grounds that it is opportunistic and undervalues the business.
Crescent submits takeover bid for Australia's Cardno
Crescent Capital Partners has submitted a takeover offer for Cardno, a listed Australian engineering company that focuses on developing physical and social infrastructure projects.
Australia's Crescent to buy Healthscope pathology business
Crescent Capital Partners has agreed to acquire the Australian pathology operations of Healthscope for A$105 million ($80.8 million).
Australia mid-market: Squeezed middle
Several Australian superannuation funds are eschewing commitments to smaller domestic GPs because they have to deploy a larger quantum of capital. If more follow suit, what does it mean for the middle market?
Australia's Crescent Capital closes Fund V at $565m
Crescent Capital Partners has reached a final close on its fifth Australia and New Zealand-focused fund at the hard cap of A$675 million ($565 million) after only 10 weeks in the market.
Tempting offers: Australian IPOs
Following a prolonged drought, Australia has seen a recent spike in private equity-backed IPOs. Is this a flash in the pan or are public market exits on the cusp of a sustained comeback?